The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
The Chemours CompanyNYSE: CC
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables turns negative
Q2 FY2026 accounts payables was -$12M, compared with $18M a year earlier. Trailing-twelve-month accounts payables was -$148M.
Context
- Accounts payables amounted to 2.8% of revenue in FY2025, up 2.7 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$12M or moves back toward the trailing-twelve-month quarterly average of -$37M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (165M) USD
- Year-over-year change
- -1733.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (165M) | -1733.3% |
| FY2024 | 2024-12-31 | (9M) | +87.5% |
| FY2023 | 2023-12-31 | (72M) | -168.6% |
| FY2022 | 2022-12-31 | 105M | -62.6% |
| FY2021 | 2021-12-31 | 281M | — |
Accounts Payables vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 accounts payables of $148M is the 5th largest of the 19 companies compared; the peer median is $23.45M.
- Its year-over-year change of -287.3% is the lowest of 18, against a peer median of +284.4%.
- Accounts payables amounts to 2.6% of revenue for CC, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.33B | +371.9% | +18.3% | 4.2% | |
| LTM Jun 2026 | $442M | +2846.7% | +4.6% | 1.2% | |
| LTM Jun 2026 | $248M | +320.3% | +47.2% | 1.5% | |
| LTM Jun 2026 | $154M | +144.4% | +0.0% | 1.5% | |
| LTM Jun 2026 | $148M | -287.3% | — | 2.6% | |
| LTM Aug 2026 | $81.22M | +394.8% | +19.0% | 2.3% | |
| LTM Sep 2026 | $75M | +181.5% | -24.1% | 0.7% | |
| LTM Sep 2026 | $47.93M | +284.4% | — | 2.4% | |
| LTM Jun 2026 | $28M | +137.3% | — | 0.8% | |
| LTM Jun 2026 | $24.26M | +71.6% | — | 1.4% | |
| LTM Mar 2026 | $22.63M | +8845.8% | — | 2.8% | |
| LTM Mar 2026 | $16.62M | +955.7% | +18.5% | 0.9% | |
| LTM Sep 2026 | $11.5M | +560.0% | — | 0.3% | |
| LTM Jun 2026 | $11.3M | -97.0% | -8.3% | 0.1% | |
| LTM Sep 2026 | $8.86M | +301.0% | — | 0.6% | |
| LTM Mar 2026 | $3.81M | +139.1% | — | 3.5% | |
| LTM Jun 2026 | $3M | -133.3% | — | 0.1% | |
| LTM Jun 2026 | $1.21M | -88.9% | -13.7% | 0.2% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CC) | $23.45M | +284.4% | +4.6% | 1.1% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| Deferred Income Tax | (77M) | 20M | (158M) | (27M) | 64M |
| Stock-Based Compensation | 34M | 27M | 19M | 15M | 21M |
| Change in Working Capital | 21M | (103M) | 620M | (1.05B) | 178M |
| Accounts Receivables | (225M) | 91M | 0 | (152M) | 106M |
| Inventory | (210M) | (294M) | 58M | (146M) | (106M) |
| Accounts Payables | 281M | 105M | (72M) | (9M) | (165M) |
| Other Working Capital | 175M | (5M) | 634M | (745M) | 343M |
| Other Non-Cash Items | (89M) | (58M) | 6M | 44M | 47M |
| Operating Cash Flow | 814M | 755M | 556M | (633M) | 264M |
| Capital Expenditures | (277M) | (307M) | (370M) | (360M) | (213M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 7M |
| Purchases of Investments | (12M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 509M | 23M | 141M | 7M | 0 |
| Investing Cash Flow | 220M | (284M) | (229M) | (353M) | (206M) |
| Debt Repayment | (208M) | (80M) | 393M | 95M | (61M) |
| Common Stock Issued | 0 | 0 | 0 | 9M | 0 |
| Common Stock Repurchased | (173M) | (495M) | (69M) | 0 | (1M) |
| Dividends Paid | (164M) | (154M) | (149M) | (148M) | (78M) |
| Other Financing Activities | (9M) | 43M | 16M | 8M | 14M |
| Financing Cash Flow | (554M) | (686M) | 172M | (36M) | (126M) |
| Effect of Forex Changes | (34M) | (32M) | 4M | (22M) | 27M |
| Net Change in Cash | 446M | (247M) | 503M | (1.04B) | (41M) |
| Free Cash Flow | 537M | 448M | 186M | (993M) | 51M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.